Australia Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Buy Report

Published: June 23, 2025 Report Code: GDME25616CCDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData’s “Australia Oncology Market Outlook to 2033” is a comprehensive databook report, covering key market data on the Australia Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The Australia Oncology Market report provides key information and data on –
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2024 company share data for Oncology Market.
• Global corporate-level profiles of key companies operating within the Australia Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

Australia Oncology is segmented as follows – _x000D_

• Colorectal Cancer Screening Tests_x000D_

• EGFR Tests_x000D_

• KRAS Tests_x000D_

• HER2 Tests_x000D_

• BRCA Tests_x000D_

• ALK Tests_x000D_

• BRAF Tests_x000D_

• BCR-ABL Tests_x000D_

• PD-L1 Tests

Reasons to Buy

The Australia Oncology Market report helps you to develop –

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Abbott Laboratories

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 5

2 Introduction 7

2.1 What Is This Report About? 7

2.2 Oncology Market Segmentation 7

2.3 Definitions of Markets Covered in the Report 9

3 Oncology Market, Australia 16

3.1 Oncology Market, Australia, Revenue ($m), 2018-2033 16

3.1.1 ALK Tests Market, Australia, Revenue ($m), by Segment, 2018-2033 19

3.1.2 BCR-ABL Tests Market, Australia, Revenue ($m), by Segment, 2018-2033 21

3.1.3 BRAF Tests Market, Australia, Revenue ($m), by Segment, 2018-2033 23

3.1.4 BRCA Tests Market, Australia, Revenue ($m), by Segment, 2018-2033 25

3.1.5 Colorectal Cancer Screening Tests Market, Australia, Revenue ($m), by Segment, 2018-2033 27

3.1.6 EGFR Tests Market, Australia, Revenue ($m), by Segment, 2018-2033 29

3.1.7 HER2 Tests Market, Australia, Revenue ($m), by Segment, 2018-2033 31

3.1.8 KRAS Tests Market, Australia, Revenue ($m), by Segment, 2018-2033 33

3.2 Oncology Market, Australia, Volume (Units), 2018-2033 35

3.2.1 ALK Tests Market, Australia, Volume (Units), by Segment, 2018-2033 38

3.2.2 BCR-ABL Tests Market, Australia, Volume (Units), by Segment, 2018-2033 40

3.2.3 BRAF Tests Market, Australia, Volume (Units), by Segment, 2018-2033 42

3.2.4 BRCA Tests Market, Australia, Volume (Units), by Segment, 2018-2033 44

3.2.5 Colorectal Cancer Screening Tests Market, Australia, Volume (Units), by Segment, 2018-2033 46

3.2.6 EGFR Tests Market, Australia, Volume (Units), by Segment, 2018-2033 48

3.2.7 HER2 Tests Market, Australia, Volume (Units), by Segment, 2018-2033 50

3.2.8 KRAS Tests Market, Australia, Volume (Units), by Segment, 2018-2033 52

3.3 Oncology Market, Australia, Average Price ($) , 2018-2033 54

3.4 Oncology Market, Australia, Company Share by Revenue ($m), 2024 58

4 Overview of Key Companies in Australia, Oncology Market 60

4.1 F. Hoffmann-La Roche Ltd 60

4.1.1 Company Overview 60

4.2 Agilent Technologies Inc 60

4.2.1 Company Overview 60

4.3 Abbott Laboratories 60

4.3.1 Company Overview 60

4.4 Roche Diagnostics International Ltd 61

4.4.1 Company Overview 61

4.5 Qiagen NV 61

4.5.1 Company Overview 61

4.6 Eiken Chemical Co Ltd 61

4.6.1 Company Overview 61

4.7 Danaher Corp 62

4.7.1 Company Overview 62

4.8 bioMerieux SA 62

4.8.1 Company Overview 62

4.9 Thermo Fisher Scientific Inc 62

4.9.1 Company Overview 62

4.10 Resonac Corporation 63

4.10.1 Company Overview 63

5 Oncology Market Pipeline Products 64

6 Financial Deals Landscape 129

6.1 Equity Offerings 129

6.1.1 Imagion Biosystems to Raise USD0.11 Million in Tranche 1 Private Placement of Shares 129

6.1.2 Imagion Biosystems to Raise USD2 Million in Private Placement of Shares 131

6.1.3 Genetic Technologies Raises USD0.21 Million in Entitlement Offering of Shares 132

6.1.4 OncoSil Medical to Raise USD1.78 Million in Private Placement of Shares 133

6.1.5 INOVIQ Raises USD4.62 Million in Private Placement of Shares 135

6.1.6 INOVIQ to Raise USD1.32 Million in SPP of Shares 136

6.1.7 Opthea Raises USD113.10 Million in Private Placement of Shares 137

6.1.8 BCAL Diagnostics to Raise USD4.12 Million in First Tranche Private Placement of Shares 139

6.1.9 BCAL Diagnostics to Raise USD2.86 Million in Second Tranche Private Placement of Shares 140

7 Recent Developments 141

7.1 Corporate Communications 141

7.1.1 Oct 08, 2024: Opthea Announces New Senior Hires 141

7.1.2 Oct 08, 2024: National Accreditation Program for Breast Centers Optimal Resources for Breast Care Standards updated to recommend use of Lymphoedema Prevention Programs, including Bioimpedance Spectroscopy 141

7.1.3 Jun 24, 2024: Clarity Receives $10 million R&D Tax Incentive Refund 142

7.2 Other Significant Developments 142

7.2.1 Feb 11, 2025: Alcidion Receives Contract With Hywel Dda University Health Board in Wales 142

7.2.2 Nov 25, 2024: ACRF Awards $20 Million to Support Transformative Australian Cancer Research: World-First Total-Body PET/CT Scanning Tech; Reducing Childhood Cancer Deaths; And Revolutionising Immunotherapies 143

7.2.3 Nov 25, 2024: Australian Cancer Research Foundation Awards $5 Million Major Grant to Launch World-Leading Childhood Cancer Early Detection, Prevention and Treatment Program 144

7.2.4 Nov 25, 2024: ACRF Funding Enables Access to State-Of-The-Art Imaging Technology Set to Improve Immunotherapy Effectiveness and Reduce Toxicity Currently Experienced in up to 30% of Patients 145

7.2.5 Oct 22, 2024: Telix Spins off Rhine Pharma to Expand Global Access to Radiopharmaceuticals 146

7.2.6 Oct 08, 2024: National Accreditation Program for Breast Centers Optimal Resources for Breast Care Standards updated to recommend use of Lymphoedema Prevention Programs, including Bioimpedance Spectroscopy 146

7.2.7 Aug 05, 2024: 10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases 147

7.3 Product News 147

7.3.1 May 29, 2025: Next-Gen Biobattery Shrinks Tumour, Paving Way for Drug-Free Cancer Treatments 147

7.3.2 Mar 24, 2025: Research Shows Importance of Genomic Testing and Targeted Therapies for Advanced Cancers 148

7.3.3 Mar 02, 2025: ONJCRI Researchers Pave the Way for Next-Generation Gene Editing in Cancer Research 149

7.3.4 Jan 16, 2025: Landmark Publication Highlights Diagnostic Potential of RoXsta 149

7.3.5 Dec 18, 2024: Clarity Announces Expansion of Pipeline With Novel Optimised FAP-Targeted Radiopharmaceutical 150

7.3.6 Oct 16, 2024: Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM) 151

7.3.7 Aug 12, 2024: Promising New Target Discovered In Pancreatic Cancer Could Boost Chemotherapy And Reduce Spread 153

7.3.8 Jun 11, 2024: DEP presentation at SNMMI radiopharmaceuticals conference 154

7.4 Strategy And Business Planning 155

7.4.1 Jun 28, 2024: Sirtex Medical Partners with MediTrust Health to Explore Innovative Payment Models for Liver Tumor Patients in China 155

8 Appendix 156

8.1 Research Methodology 157

8.1.1 Coverage 157

8.1.2 Secondary Research 157

8.1.3 Primary Research 157

8.1.4 Market Modeling and Forecasting 158

8.1.5 Company Share Analysis 159

8.1.6 Benchmarking 160

8.2 GlobalData Consulting 161

8.3 Contact Us 161

8.4 Disclaimer 161

Table

Table 1: Oncology Market, Australia, Revenue ($m), USD Constant, 2018-2033 17

Table 2: ALK Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 20

Table 3: BCR-ABL Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 22

Table 4: BRAF Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 24

Table 5: BRCA Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 26

Table 6: Colorectal Cancer Screening Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 28

Table 7: EGFR Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 30

Table 8: HER2 Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 32

Table 9: KRAS Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 34

Table 10: Oncology Market, Australia, Volume (Units), 2018-2033 36

Table 11: ALK Tests Market, Australia, Volume (Units), 2018-2033 39

Table 12: BCR-ABL Tests Market, Australia, Volume (Units), 2018-2033 41

Table 13: BRAF Tests Market, Australia, Volume (Units), 2018-2033 43

Table 14: BRCA Tests Market, Australia, Volume (Units), 2018-2033 45

Table 15: Colorectal Cancer Screening Tests Market, Australia, Volume (Units), 2018-2033 47

Table 16: EGFR Tests Market, Australia, Volume (Units), 2018-2033 49

Table 17: HER2 Tests Market, Australia, Volume (Units), 2018-2033 51

Table 18: KRAS Tests Market, Australia, Volume (Units), 2018-2033 53

Table 19: Oncology Market, Australia, Average Price ($), 2018-2033 54

Table 20: Oncology Market, Australia, Company Share by Revenue ($m), 2024 59

Table 21: Oncology Market Pipeline Products 64

Table 22: Imagion Biosystems to Raise USD0.11 Million in Tranche 1 Private Placement of Shares 129

Table 23: Imagion Biosystems to Raise USD2 Million in Private Placement of Shares 131

Table 24: Genetic Technologies Raises USD0.21 Million in Entitlement Offering of Shares 132

Table 25: OncoSil Medical to Raise USD1.78 Million in Private Placement of Shares 133

Table 26: INOVIQ Raises USD4.62 Million in Private Placement of Shares 135

Table 27: INOVIQ to Raise USD1.32 Million in SPP of Shares 136

Table 28: Opthea Raises USD113.10 Million in Private Placement of Shares 137

Table 29: BCAL Diagnostics to Raise USD4.12 Million in First Tranche Private Placement of Shares 139

Table 30: BCAL Diagnostics to Raise USD2.86 Million in Second Tranche Private Placement of Shares 140

Table 31: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 158

Figures

Figure 1: Oncology Market, Australia, Revenue ($m), USD Constant, 2018-2033 16

Figure 2: ALK Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 19

Figure 3: BCR-ABL Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 21

Figure 4: BRAF Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 23

Figure 5: BRCA Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 25

Figure 6: Colorectal Cancer Screening Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 27

Figure 7: EGFR Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 29

Figure 8: HER2 Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 31

Figure 9: KRAS Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033 33

Figure 10: Oncology Market, Australia, Volume (Units), 2018-2033 35

Figure 11: ALK Tests Market, Australia, Volume (Units), 2018-2033 38

Figure 12: BCR-ABL Tests Market, Australia, Volume (Units), 2018-2033 40

Figure 13: BRAF Tests Market, Australia, Volume (Units), 2018-2033 42

Figure 14: BRCA Tests Market, Australia, Volume (Units), 2018-2033 44

Figure 15: Colorectal Cancer Screening Tests Market, Australia, Volume (Units), 2018-2033 46

Figure 16: EGFR Tests Market, Australia, Volume (Units), 2018-2033 48

Figure 17: HER2 Tests Market, Australia, Volume (Units), 2018-2033 50

Figure 18: KRAS Tests Market, Australia, Volume (Units), 2018-2033 52

Figure 19: Oncology Market, Australia, Company Share (%), 2024 58

Australia Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others standard reports

Currency USD

Single User

$4,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports

Medical Devices

New

Global M&A Deals in H1 2026 - Top Themes by…

Medical Devices

New

Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…

Medical Devices

New

AI-designed Materials: Market Trends and Innovations

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Australia Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others in real time.

Access a live Australia Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Australia Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports